BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

OrthoMimetics Release: First Patient Treated With Implant For Regenerative Repair Of Articular Cartilage And Bone


3/6/2009 11:46:25 AM

Cambridge UK, 06 March 2009 Orthomimetics, the UK based regenerative medicine company, has enrolled the first patient in its European pilot clinical trial of Chondromimetic, the company's flagship product for the repair of articular cartilage and bone.

The single-centre study is being conducted under the supervision of world-renowned surgeon Professor Laszlo Hangody in Budapest, Hungary. The trial will evaluate the safety and efficacy of Chondromimetic using multiple outcome variables, and marks the beginning of Orthomimetics' comprehensive evidence-based clinical program to support the launch of Chondromimetic.

Chondromimetic is a resorbable medical device that supports the body's natural repair mechanisms to encourage the simultaneous repair of both articular cartilage and the bone to which it is attached. Chondromimetic harnesses Orthomimetics' proprietary materials technology that produces novel mechanical properties without the need for synthetic polymers or other additives that can produce adverse degradation products.

Commenting on the commencement of the trial, Andrew Lynn, CEO of Orthomimetics said: 'Surgeons today are rightly demanding a higher level of evidence to demonstrate the efficacy of products used to treat their patients. By working with respected surgeons such as Professor Hangody, Orthomimetics is committed to being a leader in providing sound clinical evidence to demonstrate the long-term benefit of our products.'

This first enrolment follows CE-mark approval for Chondromimetic, which enables the company to market the product in Europe.

Orthomimetics Limited is a medical technology company that specialises in the design, development, and manufacture of regenerative medical implants and minimally invasive delivery systems for the treatment of sports injuries, trauma and other conditions that affect knees, ankles and other articular joints. Formed in 2005 as the first spin-out venture from the Cambridge-MIT Institute, the company is bringing to market a line of medical device products designed to improve the treatment outcome of first-line surgical procedures for the regenerative repair of articular cartilage, meniscus, ligament and tendon injuries using natural biomaterials. These products are engineered to be compatible with existing surgical techniques and to work in combination with emerging cell- and biologics-based products.

For further information on Orthomimetics please go to our website: www.orthomimetics.com

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES